10 Firms Dominating the Market; 5 at All-Time Highs

3. Travere Therapeutics, Inc. (NASDAQ:TVTX)

Travere Therapeutics climbed to a fresh record high on Friday, as investors took heart from a stellar earnings performance and cues that the company would kick off the last month of the year on a strong note.

At intra-day trading, the stock soared to its highest price of $35.34 before trimming gains to end the day just up by 18.58 percent at $35.16 apiece.

Based on its financial statement on Thursday, Travere Therapeutics, Inc. (NASDAQ:TVTX) swung to a net income of $25.7 million in the third quarter of the year from a $54.8 million net loss in the same period last year.

Total revenues expanded by 162 percent to $164.8 million from $62.9 million year-on-year, helped by strong sales from its kidney disease treatment, Filspari.

According to Travere Therapeutics, Inc. (NASDAQ:TVTX), the drug incurred $90.9 million in sales in the US alone, representing a 155 percent growth year-on-year.

“We delivered outstanding commercial performance in the third quarter, reflecting the growing role of FILSPARI as a foundational therapy in IgAN. This success underscores the strength of our commercial execution and the expanding confidence in FILSPARI among physicians and patients,” Travere Therapeutics, Inc. (NASDAQ:TVTX) President and CEO Eric Dube said.

“We continue to be pleased with the progress of our sNDA review in FSGS and are actively preparing for a potential FDA approval early next year. We are also making meaningful progress toward restarting the pivotal HARMONY Study of pegtibatinase and have positioned the company to support long-term growth. We are entering the final months of 2025 in a position of strength as we remain focused on execution and on expanding our impact for people living with rare diseases,” he noted.